The influence of growth hormone on pediatric body composition: A systematic review.

Plain-language guide to PMID 36843617 (2023): systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 36843617
Journal: Frontiers in endocrinology
Year: 2023
Study type: Systematic Review
Authors: Ferruzzi A et al. (9 authors)
DOI: 10.3389/fendo.2023.1093691

What This Paper Covers, in Plain Language

What It Covers

This systematic review looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Growth hormone (GH) affects metabolism and regulates growth in childhood.

The most prominent feature of GH deficiency (GHD) in children is diminished height velocity that eventually leads to short stature.

Who the Included Studies Covered

The age groups tagged for this paper are children.

The PubMed, Science Direct, Cochrane Trials, and Embase databases, were searched with keywords including "GH", "body composition", "children", and "growth hormone" for English-language articles, published between January 1999 and March 2021.

Two reviewers independently evaluated the search results and identified studies for inclusion based on the following criteria: participants had a confirmed diagnosis of GHD (as defined in each study); participants were pediatric patients who were receiving GH or had stopped GH treatment, regardless of whether they were pre- or post-pubertal; the intervention was recombinant human GH (rhGH; somatropin); and outcomes included changes in body composition during or after stopping GH therapy.

How the Review Was Done

Data extracted from each study included study quality, study sample characteristics, study interventions, and body composition.

Data on fat-free mass and LBM were combined into a single category of LBM.

What Was Measured

Topics PubMed links to this paper include Body Composition, Dwarfism, Pituitary, Growth Hormone, Human Growth Hormone and Hypopituitarism.

Author keywords: fat mass, growth hormone deficiency and lean body mass.

What This Means in Plain Language

This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.